$1.39
+0.08 (+6.11%)
Open$1.32
Previous Close$1.31
Day High$1.45
Day Low$1.30
52W High$2.66
52W Low$1.05
Volume—
Avg Volume1.31M
Market Cap181.14M
P/E Ratio—
EPS$-1.14
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+1,751.1% upside
Current
$1.39
$1.39
Target
$25.73
$25.73
$15.89
$25.73 avg
$34.39
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 18.10M | 17.71M | 19.64M |
| Net Income | 3.87M | 3.06M | 4.04M |
| Profit Margin | 21.4% | 17.3% | 20.6% |
| EBITDA | 5.83M | 6.29M | 6.55M |
| Free Cash Flow | 3.85M | 4.93M | 3.44M |
| Rev Growth | +0.2% | -1.6% | +10.4% |
| Debt/Equity | 0.48 | 0.65 | 0.65 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |